Cipla Q4 FY25 Results: Net Profit Rises 30% YoY, ₹16 Dividend Announced

Cipla reported a 30.12% year-on-year (YoY) rise in its consolidated net profit for Q4FY25 to ₹1,221.84 crore, up from ₹939.04 crore in Q4FY24. Revenue from sales increased by 8.5% YoY to ₹6,597.72 crore compared to ₹6,082.37 crore a year ago. 

Pharmaceutical and New Ventures Segment Performance 

The main pharmaceuticals segment earned ₹6,503.63 crore in revenue, which is 8.5% higher than ₹5,996.38 crore in the same quarter last year. In Q4FY25, Cipla’s new ventures generated ₹288.48 crore in revenue, marking a robust year-on-year growth of 35.44%. 

Read More, BEML Interim Dividend of ₹15 Record Date Tomorrow, May 15, 2025.  

Operating Performance 

Cipla's EBITDA (earnings before interest, tax, depreciation, and amortisation) rose 17% YoY to ₹1,538 crore. The EBITDA margin also improved by 150 basis points, reaching 22.8%. 

Full-Year FY25 Performance 

For the full fiscal year, Cipla’s net profit increased by 28% YoY to ₹5,273 crore. Total revenue for FY25 stood at ₹27,548 crore, up 8% YoY. The EBITDA margin for the year was a strong 25.9%, helped by a better product mix and operational efficiencies. 

Business Highlights 

• Cipla’s "One-India" business grew by 7% YoY. 
   

• The branded prescription drugs outpaced overall market growth. 
   

• The trade generics segment recovered its growth momentum.  
   

• Consumer health brands continued to lead their categories.  

Strong Global Growth 

• US business posted a record-high revenue of $934 million in FY25. 

• Cipla's business in Africa recorded a 12% year-on-year growth when measured in US dollar terms. 

• Emerging markets and Europe saw 15% YoY revenue growth, driven by strong market focus. 

Future Outlook 

Cipla plans to focus on: 

• Growing its major markets  

• Strengthening flagship brands  

• Investing in its future product pipeline  

• Addressing regulatory challenges 

Dividend Declaration 

Cipla announced a final dividend of ₹13 per share for FY25. Additionally, a special dividend of ₹3 per share was declared to mark Cipla’s 90th anniversary. Total dividend for FY25 amounts to ₹16 per share (face value ₹2). 

About Cipla 

Cipla Ltd is a leading Indian MNC (multinational pharmaceutical company) based in Mumbai. It develops medicines for various health issues, including respiratory problems, heart diseases, arthritis, diabetes, depression, and children’s health. 

As of 09:35 AM, May 14, 2025, Cipla share price is trading at ₹1,500.10, with a market capitalisation of ₹1.21 lakh crore. The stock has a P/E ratio of 24.30 and offers a dividend yield of 0.87%, with a quarterly dividend amount of ₹3.26. 

Conclusion 

Cipla delivered a strong performance in Q4 and FY25, driven by consistent growth across domestic and global markets. With record U.S. sales and robust margins, the company is well-positioned for future growth as it continues to strengthen its core businesses and invest in new opportunities. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.     

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.